KRAS and neoplasm: It has been reported that colorectal cancer patients with a mutation allele frequency (MAF)/variant allele frequency (VAF) of 0.1~5% in KRAS mutation in tumor tissue might benefit from the addition of anti-EGFR (cetuximab) to FOLFIRI chemotherapy [4].